Idiopathic Intracranial Hypertension

Illustration of the brain and fluid spaces under raised pressure
Idiopathic intracranial hypertension is raised pressure of the fluid around the brain with no tumour or other structural cause.
Infographic: raised spinal fluid pressure, no tumor found, swelling of the optic nerve
The page describes raised cerebrospinal fluid pressure without a mass on imaging, and optic nerve swelling that can cause permanent vision loss.
Retinal photograph of a swollen optic disc
Papilledema, a swollen optic disc seen at the back of the eye, is the sign that links this condition to vision loss.

Table of Contents

  1. Overview
  2. Demographics and Risk Factors
  3. Secondary Causes and Diagnosis of Exclusion
  4. Modified Dandy Criteria
  5. Clinical Features
  6. Treatment
  7. Vision Monitoring and Prognosis
  8. Key Research Papers
  9. Connections
  10. Featured Videos

Overview

Idiopathic intracranial hypertension (IIH), also called pseudotumor cerebri (PTC), is a condition of elevated cerebrospinal fluid (CSF) pressure exceeding 25 cmH₂O in adults (28 cmH₂O in children) in the absence of a structural lesion, hydrocephalus, or abnormal cerebrospinal fluid composition. The outdated term "benign intracranial hypertension" is no longer used because IIH is not benign — it can cause permanent vision loss from optic nerve damage. The condition mimics a brain tumor clinically (hence "pseudotumor cerebri") but neuroimaging reveals no mass lesion. IIH is classified as idiopathic only after secondary causes of elevated intracranial pressure have been excluded.

Demographics and Risk Factors

IIH predominantly affects women of reproductive age, with a female-to-male ratio of approximately 9:1. Obesity is present in 90% of cases, and the rising prevalence of IIH closely parallels the global obesity epidemic. The classic patient profile is an obese woman of childbearing age presenting with headache and visual disturbances.

Risk factors include:

In a UK study of 2,760 women with the condition, compared with women of the same age and body mass index, heart disease, heart failure and stroke together were about twice as common (adjusted hazard ratio 2.10). New cases more than tripled from 2005 to 2017, from 2.5 to 9.3 per 100,000 person-years.

Secondary Causes and Diagnosis of Exclusion

IIH is a diagnosis of exclusion. Secondary causes of elevated intracranial pressure are ruled out first.

Medications and toxins (reported associations): tetracyclines, vitamin A and retinoids (isotretinoin prescribed for acne), oral contraceptives, corticosteroid withdrawal, recombinant growth hormone, excess thyroid hormone replacement, lithium, anabolic steroids.

Venous outflow obstruction: cerebral venous sinus thrombosis (the 2018 UK consensus guidelines call CT or MR venography mandatory to exclude it, and treatment differs fundamentally), dural arteriovenous fistula.

Systemic conditions: hypothyroidism, hypoparathyroidism, iron deficiency anemia, systemic lupus erythematosus, chronic kidney disease, hypervitaminosis A.

Diagnostic workup for exclusion:

Modified Dandy Criteria

The Modified Dandy Criteria are used to confirm the diagnosis of IIH:

  1. Symptoms and/or signs of increased intracranial pressure: headache, papilledema, visual obscurations, diplopia from palsy of one or both sixth cranial nerves, pulsatile tinnitus
  2. Lumbar puncture opening pressure ≥25 cmH₂O with normal cerebrospinal fluid composition (protein, glucose, and cell count all normal)
  3. Normal neuroimaging: no intracranial mass, no hydrocephalus, no meningeal enhancement, no structural abnormality
  4. No other identifiable cause for elevated intracranial pressure

Note: IIH without papilledema is recognized as a subset where all criteria except papilledema are met. In a Utah series of 353 patients it made up 5.7%.

Clinical Features

Headache (present in ~94% of patients): Daily or near-daily headache, often worse in the morning, aggravated by Valsalva maneuvers (coughing, straining), and may worsen when supine. The character is throbbing, retro-orbital, or pressure-like and can mimic migraine or tension headache. Headache in the setting of papilledema is a recognized pointer to IIH.

Papilledema (bilateral optic disc swelling): The hallmark finding. Elevated cerebrospinal fluid pressure is transmitted along the optic nerve sheath, causing disc swelling visible on fundoscopy. If prolonged, papilledema leads to progressive optic nerve fiber loss and permanent visual field defects — the most feared complication of IIH.

Transient visual obscurations: Brief (seconds-long) episodes of graying, blackening, or blurring of vision provoked by changes in posture, Valsalva, or bending forward. These reflect transient optic nerve ischemia from pressure spikes.

Pulsatile tinnitus: A whooshing sound synchronous with the heartbeat, caused by turbulent venous flow through stenotic transverse sinuses under high pressure. This symptom is characteristic of IIH and is not common in most other headache disorders.

Diplopia from sixth cranial nerve palsy: Unilateral or bilateral sixth nerve palsy causing horizontal diplopia. This is a false localizing sign — the nerve is injured by elevated intracranial pressure regardless of where the pressure originates, not because there is a primary lesion of the nerve.

Visual field loss: Enlargement of the blind spot (enlarged physiological blind spot) is the earliest detectable change on perimetry. Progressive loss follows an inferior nasal pattern, then arcuate defect, and eventually tunnel vision. Visual field defects can become permanent if intracranial pressure is not controlled.

Cognitive symptoms: Some patients report brain fog, difficulty with concentration, and word-finding difficulties. These are underrecognized but can significantly impact quality of life.

Treatment

Weight loss (first-line for obese patients): The 2018 UK consensus guidelines call weight loss the only disease-modifying therapy in typical IIH. They state that the amount needed to put the disease into remission is not known, and that up to 15% of weight loss was required in one cohort. In the IIH Treatment Trial (IIHTT, 165 participants), everyone received a low-sodium weight-reduction diet, and the trial compared acetazolamide with placebo. Visual field (perimetric mean deviation) improved 1.43 dB with acetazolamide and 0.71 dB with placebo, a difference of 0.71 dB (95% CI 0 to 1.43 dB; P = .050), which its authors call modest, with clinical importance still to be determined. Weight fell 7.50 kg with acetazolamide and 3.45 kg with placebo.

Weight-loss surgery: A 2021 randomized trial of 66 women with a body mass index of 35 or more compared bariatric surgery with a community weight programme. Pressure in the head was 6.0 cm of cerebrospinal fluid lower at 12 months and 8.2 cm lower at 24 months after surgery, with weight 26.6 kg lower at 24 months and better quality of life.

Glucagon-like peptide-1 drugs: In a small 2023 placebo-controlled trial of 16 women, exenatide lowered pressure by 5.6 to 6.4 cm of cerebrospinal fluid. Its authors wrote that the data support moving to a larger phase 3 trial. A 2026 review of 8 studies and 13,243 patients linked this drug family to less optic nerve swelling and headache, but its authors call the evidence low-certainty because most of the studies were observational.

Acetazolamide: First-line pharmacological treatment. A carbonic anhydrase inhibitor that reduces cerebrospinal fluid production at the choroid plexus. Starting dose 500 mg twice daily, titrated to 2,000–4,000 mg/day as tolerated. The IIHTT (Wall et al., 2014) showed modest improvement in visual field, with improvement in papilledema grade and vision-related quality of life. Common side effects include paresthesias in hands and feet (nearly universal), dysgeusia (metallic taste of carbonated drinks), hypokalemia, kidney stone formation, and fatigue. Tolerance varies: in the trial 44% reached 4 g a day, and in another cohort 48% stopped because of side effects at a mean of 1.5 g. The label lists as contraindications hypersensitivity to acetazolamide (cross-sensitivity with sulfa drugs is possible), low blood sodium or potassium, marked kidney or liver disease, adrenal gland failure, hyperchloremic acidosis and cirrhosis.

Topiramate: An alternative or adjunct to acetazolamide. Also a carbonic anhydrase inhibitor with the added benefit of promoting weight loss. Useful when acetazolamide is not tolerated. The 2018 UK consensus guidelines record safety facts that matter because most patients are women of childbearing age: there is clear evidence of a higher rate of fetal abnormalities after topiramate use, and it can make the contraceptive pill and other hormonal contraceptives less effective. Its side effects include depression and slowed thinking.

Furosemide: The 2018 UK consensus guidelines state that the role of other diuretics such as furosemide is not certain, though some clinicians use them as alternative therapies.

Surgical options for vision-threatening IIH:

Repeat lumbar puncture: Provides temporary intracranial pressure reduction. Primarily used diagnostically or as a temporary bridge while awaiting surgical intervention. Not a long-term solution.

Vision Monitoring and Prognosis

Serial visual field testing with Humphrey automated perimetry (24-2 program) every 1–3 months during active disease is the standard follow-up. Optical coherence tomography (OCT) of the retinal nerve fiber layer (RNFL) provides objective measurement of optic nerve damage. Fundoscopy to grade papilledema is part of each visit.

With timely weight loss and medical treatment, most patients achieve intracranial pressure control and vision stabilization. Vision loss occurs in 10–25% of patients; severe vision loss in approximately 5%. Recurrence is common with weight regain. Chronic intractable headache persists in some patients even after intracranial pressure normalization. Pregnancy can trigger IIH exacerbation. The 2018 UK consensus guidelines state that it is difficult to make any safe recommendations on using acetazolamide during pregnancy and that its manufacturers do not recommend it, on the basis of birth defects seen in rodents.

Key Research Papers

  1. Wall M, et al. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol. 2014;71(6):693-701. — PubMed PMID: 24756302
  2. NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee, Wall M, McDermott MP, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014;311(16):1641-51. — PubMed PMID: 24756514
  3. Mollan SP, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018;89(10):1088-1100. — PubMed PMID: 29903905
  4. Friedman DI, et al. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81(13):1159-1165. — PubMed PMID: 23966248
  5. Markey KA, et al. Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurol. 2016;15(1):78-91. — PubMed PMID: 26700907
  6. Celebisoy N, et al. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand. 2007;116(5):322-327. — PubMed PMID: 17922725
  7. Azzam AY, Mortezaei A, Morsy MM, et al. Venous sinus stenting for idiopathic intracranial hypertension: an updated meta-analysis. J Neurol Sci. 2024;459:122948. — PubMed PMID: 38457956
  8. Thurtell MJ, Wall M. Idiopathic intracranial hypertension (pseudotumor cerebri): recognition, treatment, and ongoing management. Curr Treat Options Neurol. 2013;15(1):1-12. — PubMed PMID: 23136035
  9. Rowe FJ, Sarkies NJ. The relationship between obesity and idiopathic intracranial hypertension. Int J Obes Relat Metab Disord. 1999;23(1):54-59. — PubMed PMID: 10094577
  10. Adderley NJ, Subramanian A, Nirantharakumar K, et al. Association between idiopathic intracranial hypertension and risk of cardiovascular diseases in women in the United Kingdom. JAMA Neurol. 2019;76(9):1088-1098. — PubMed PMID: 31282950
  11. Thambisetty M, et al. Fulminant idiopathic intracranial hypertension. Neurology. 2007;68(3):229-232. — PubMed PMID: 17224579
  12. McGeeney BE, Friedman DI. Pseudotumor cerebri pathophysiology. Headache. 2014;54(3):445-458. — PubMed PMID: 24433163
  13. Mollan SP, Mitchell JL, Ottridge RS, et al. Effectiveness of bariatric surgery vs community weight management intervention for the treatment of idiopathic intracranial hypertension: a randomized clinical trial. JAMA Neurol. 2021;78(6):678-686. — PubMed PMID: 33900360
  14. Mitchell JL, Lyons HS, Walker JK, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023;146(5):1821-1830. — PubMed PMID: 36907221
  15. Falcão L, Brenner LBO, Machado Magalhães PL, et al. Glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: a systematic review and meta-analysis. Headache. 2026;66(9):2117-2128. — PubMed PMID: 42619634
  16. Digre KB, Nakamoto BK, Warner JE, et al. A comparison of idiopathic intracranial hypertension with and without papilledema. Headache. 2009;49(2):185-93. — PubMed PMID: 19222592

Back to Table of Contents

Connections

↑ Back to Table of Contents